Category Venues

World Health Assembly Concludes With Actions On Range Of Issues

The 68th World Health Assembly (WHA), which took place from 18-26 May, was characterised as one of the most successful annual assemblies ever by Margaret Chan, World Health Organization director general. From the standpoint of intellectual property, access and innovation, this may be debatable. Below is a guide to the main accomplishments highlighted by Intellectual Property Watch.

These include: action plans to fight antibiotic resistance and to boost vaccinations, extension of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA), incremental progress on alternative research and development for neglected diseases, status of the pandemic influenza preparedness framework, response to emergencies like Ebola, and WHO’s relationship with lobbyists and donors.

An Interview With WIPO Director General Francis Gurry On The New Lisbon Act For GIs

Members of the Lisbon Agreement for the Protection of Appellations of Origin and their International Registration on 20 May agreed on a new Act of the agreement, extending protection previously granted only to appellations of origins to geographical indications. The World Intellectual Property Organization is responsible for this agreement. After the signing ceremony at WIPO, Intellectual Property Watch sat down with WIPO Director General Francis Gurry to discuss the new Act.

WHO Advances R&D Financing Effort; Global R&D Observatory To Launch In January

World Health Organization members in committee this week took note of a report by the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG), which was set up to find ways to fund research on diseases afflicting poor populations which have little market incentive for the private sector. The report included a proposal for a voluntary pooled fund that would focus on the development of effective and affordable health technologies for such neglected diseases.

WHO Debates Plan To Fight Antibiotic Resistance

World Health Organization members this week are debating a plan to address the global problem of increasing resistance to existing antibiotics and the lack of new treatments to replace them. Today, discussions on antimicrobial resistance went to informals to try to resolve outstanding issues.

Five Challenges Filed Against Gilead Patent Claims For Hepatitis C Drug

Pharmaceutical company Gilead Sciences has been noted first for developing a treatment for hepatitis C, which afflicts tens of millions around the world, and then for pricing it at jaw-dropping prices ($1000 per pill) in the United States and elsewhere. Now a group of health advocates has challenged Gilead's patent applications in five emerging economies.